Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist

Abstract

Eltrombopag is a first-in-class, orally bioavailable, small-molecule, nonpeptide agonist of the thrombopoietin receptor (TpoR), which is being developed as a treatment for thrombocytopenia of various etiologies. In vitro studies have demonstrated that the activity of eltrombopag is dependent on expression of TpoR, which activates the signaling transducers and activators of transcription (STAT) and mitogen-activated protein kinase signal transduction pathways. The objective of this preclinical study is to determine if eltrombopag interacts selectively with the TpoR to facilitate megakaryocyte differentiation in platelets. Functional thrombopoietic activity was demonstrated by the proliferation and differentiation of primary human CD34+ bone marrow cells into CD41+ megakaryocytes. Measurements in platelets in several species indicated that eltrombopag specifically activates only the human and chimpanzee STAT pathways. The in vivo activity of eltrombopag was demonstrated by an increase of up to 100% in platelet numbers when administered orally (10 mg/kg per day for 5 days) to chimpanzees. In conclusion, eltrombopag interacts selectively with the TpoR without competing with Tpo, leading to the increased proliferation and differentiation of human bone marrow progenitor cells into megakaryocytes and increased platelet production. These results suggest that eltrombopag and Tpo may be able to act additively to increase platelet production.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 31

1. 1.

   Paquette RL. Diagnosis and management of aplastic anemia and myelodysplastic syndrome. Oncology (Williston Park). 2002;16(suppl 10):153-161.

   Not in our library

2. 2.

   Stevens W, Koene H, Zwaginga JJ, et al. Chronic Idiopathic Thrombocytopenic purpura: Present strategy, guidelines and new insights. Neth J Med. 2006;64:356-363.

   Not in our library

3. 3.

   Tijssen MR, van der Schoot CE, Voermans C, et al. Clinical approaches involving thrombopoietin to shorten the period of thrombocytopenia after high-dose chemotherapy. Transfus Med Rev. 2006;20:283-293.

   Not in our library10.1016/j.tmrv.2006.05.003

4. 4.

   Giannini EG. Review article: Thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther. 2006;23:1055-1065.

   Not in our library10.1111/j.1365-2036.2006.02889.x

5. 5.

   Bordin G, Ballare M, Zigrossi P, et al. A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: A direct role of HCV in bone marrow exhaustion? Clin Exp Rheumatol. 1995;13(suppl 13):S39-S43.

   Not in our library

6. 6.

   Kaushansky K, Drachman JG. The molecular and cellular biology of thrombopoietThe primary regulator of platelet production. Oncogene. 2002;21:3359-3367.

   Not in our library10.1038/sj.onc.1205323

7. 7.

   Kuter DJ, Begley CG. Recombinant human thrombopoietBasic biology and evaluation of clinical studies. Blood. 2002;100:3457-3469.

   Not in our library10.1182/blood.v100.10.3457

8. 8.

   Ezumi Y, Takayama H, Okuma M. Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett. 1995;374:48-52.

   Not in our library10.1016/0014-5793(95)01072-m

9. 9.

   Drachman JG, Millet KM, Kaushansky K. Thrombopoietin signal transduction requires functional JAK2, not TYK2. J Biol Chem. 1999;274:13480-13484.

   Not in our library10.1074/jbc.274.19.13480

10. 10.

    Rojnuckarin P, Drachman JG, Kaushansky K. Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: Role in endomitosis. Blood. 1999;94:1273-1282.

    Not in our library

11. 11.

    Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. 1994;77:1117-1124.

    Not in our library10.1016/0092-8674(94)90450-2

12. 12.

    de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369:533-538.

    Not in our library10.1038/369533a0

13. 13.

    Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994;369:568-571.

    Not in our library10.1038/369568a0

14. 14.

    Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994;369:565-568.

    Not in our library10.1038/369565a0

15. 15.

    Wendling F, Maraskovsky E, Debili N, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature. 1994;369:571-574.

    Not in our library10.1038/369571a0

16. 16.

    Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241-3248.

    Not in our library10.1182/blood.v98.12.3241

17. 17.

    Erickson-Miller CL, DeLorme E, Tian SS, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005;33:85-93.

    Not in our library10.1016/j.exphem.2004.09.006

18. 18.

    Duffy KJ, Darcy MG, Delorme E, et al. Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis. J Med Chem. 2001;44:3730-3745.

    Not in our library10.1021/jm010283l

19. 19.

    Duffy KJ, Shaw AN, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics. J Med Chem. 2002;45:3573-3575.

    Not in our library10.1021/jm025535c

20. 20.

    Duffy KJ, Price AT, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimics. J Med Chem. 2002;45:3576-3578.

    Not in our library10.1021/jm0255365

21. 21.

    Erickson-Miller C, DeLorme E, Iskandar M, et al. Species specificity and receptor domain interaction of a small molecule TpoR agonist. Blood. 2004;104:2909.

    Not in our library

22. 22.

    Nakamura T, Miyakawa Y, Miyamura A, et al. A novel nonpetidyl human c-Mpl activator stimulates human megakaryocytopoiesis and thrombosis. Blood. 2006;107:4300-4307.

    Not in our library10.1182/blood-2005-11-4433

23. 23.

    Kim M-J, Park SH, Opella SJ, et al. NMR structural studies of interactions of a small, nonpeptidyl Tpo mimic with the thrombopoietin receptor extracellular juxtamembrane and transmembrane domains. J Biol Chem. 2007;282:14253-14261.

    Not in our library10.1074/jbc.m611616200

24. 24.

    Erhardt J, Tapley P, Erickson-Miller C. A low molecular weight, orally active TpoR agonist, SB-497115, does not prime platelets for activation or agonist-induced aggregation in vitro. Exper Hematol. 2005;33(1):365.

    Not in our library

25. 25.

    Jenkins JM, Williams D, Deng Y, et al. Phase I clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007;109:4739-4741.

    Not in our library10.1182/blood-2006-11-057968

26. 26.

    Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood. 1996;88:511-521.

    Not in our library

27. 27.

    Harker LA, Roskos LK, Marzec UM, et al. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood. 2000;95:2514-2522.

    Not in our library

28. 28.

    Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237-2247.

    Not in our library10.1056/nejmoa073275

29. 29.

    Kantarjian HM, Giles FJ, Fenaux P, et al. Evaluating safety and efficacy of AMG 531 for the treatment of thrombocytopenic patients with myelodysplastic syndrome (MDS): Preliminary results of a phase 1/2 study. J Clin Oncol. 2007;25(18):7032.

    Not in our library

30. 30.

    McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357:2227-2236.

    Not in our library10.1056/nejmoa073255

31. 31.

    Duffy KJ, Erickson-Miller CL, Metcalf BW, Dillon S. The discovery of eltrombopag, an orally bioavailable TpoR agonist. Target Validation in Drug Discovery. 2007;241-254.

    Not in our library

Cited by papers we hold 2

• Pro- and Anti-Inflammatory Prostaglandins and Cytokines in Humans: A Mini Review · 2023
  No notice
• Advances in Diagnosis and Treatments for Immune Thrombocytopenia · 2016
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.